Quantitating Overall Neuropathic Symptoms, Impairments, and Outcomes

Peripheral Neuropathy

Volumn 1, Issue , 2005, Pages 1031-1051

  Dyck, Peter J ^a   Hughes, Richard A C ^b   O'Brien, Peter C ^a  

^a MAYO CLINIC   (United States)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882855831     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-7216-9491-7.50043-0     Document Type: Chapter

References (60)

1. Ametov A.S., Barinov A., Dyck P.J., et al. The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid. The Sydney Trial. Diabetes Care 2003, 26:770.
2. Apfel S.C., Schwartz S., Adornato B.T., et al. Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: a randomized controlled trial. JAMA 2000, 284:2215.
3. Bamford J.M., Sandercock P.A., Warlow C.P., Slattery J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1989, 20:828.
4. Bernsen A.J.A.M., De Jager A.E.J., Schmitz P.I.M., van der Meche F.G.A. Long-term impact on work and private life after Guillain-Barre syndrome. J. Neurol. Sci. 2002, 201:13.
5. Burns T.M., Taly A., O'Brien P.C., Dyck P.J. Clinical versus quantitative vibration assessment: improving clinical performance. J. Peripher. Nerv. Syst. 2002, 7:112.
6. Capildeo R., Orgogozo J.-M. Methods in clinical trials in neurology. Vascular and Degenerative Brain Disease 1988, 327. Macmillan Press, London.
7. Chalder T., Berelowitz G., Pawlikowska T., et al. Development of a fatigue scale. J. Psychosom. Res. 1993, 37:147.
8. Cocchiarella L., Andersson G.B.J. Guides to the Evaluation of Permanent Impairment 2001, 613. American Medical Association Press, Chicago.
9. Comi G., Swan A.V., Hughes R.A.C. Randomized controlled trial of IVIg in paraproteinaemic demyelinating neuropathy. J. Neurol. Sci. 2001, 187(Suppl. 1):S120. for the INCAT Group.
10. Cornblath D.R., Chaudhry V., Carter K., et al. Total neuropathy score: validation and reliability study. Neurology 1999, 53:1660.
11. Day S. Dictionary for Clinical Trials 1999, 217. John Wiley & Sons, Chichester, GBR.
12. Dyck, P. J.: Neurophysiological evaluation of restorative surgery of nerve and muscle. Invited contribution to the 6th International Congress of Electromyography in Stockholm, Sweden, Symposia 85-86, June 17-20, 1979.
13. Dyck P.J., Daube J., O'Brien P., et al. Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N. Engl. J. Med. 1986, 314:461.
14. Dyck P.J., Davies J.L., Litchy W.J., O'Brien P.C. Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort. Neurology 1997, 49:229.
15. Dyck P.J., Davies J.L., Wilson D.M., et al. Risk factors for severity of diabetic polyneuropathy: intensive longitudinal assessment of the Rochester Diabetic Neuropathy Study cohort. Diabetes Care 1999, 22:1479.
16. Dyck P.J., Karnes J., O'Brien P.C., Swanson C.J. Neuropathy symptom profile in health, motor neuron disease, diabetic neuropathy, and amyloidosis. Neurology 1986, 36:1300.
17. Dyck P.J., Kratz K.M., Lehman K.A., et al. The Rochester Diabetic Neuropathy Study: design, criteria for types of neuropathy, selection bias, and reproducibility of neuropathic tests. Neurology 1991, 41:799.
18. Dyck P.J., Litchy W.J., Kratz K.M., et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann. Neurol. 1994, 36:838.
19. Dyck P.J., Litchy W.J., Lehman K.A., et al. Variables influencing neuropathic endpoints: the Rochester Diabetic Neuropathy Study of Healthy Subjects (RDNS-HS). Neurology 1995, 45:1115.
20. Dyck P.J., Low P.A., Windebank A.J., et al. Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance. N. Engl. J. Med. 1991, 325:1482.
21. Dyck P.J., O'Brien P.C., Oviatt K.F., et al. Prednisone improves chronic inflammatory demyelinating polyradicu-loneuropathy more than no treatment. Ann. Neurol. 1982, 11:136.
22. Dyck P.J., Sherman W.R., Hallcher L.M., et al. Human diabetic endoneurial sorbitol, fructose, and myo-inositol related to sural nerve morphometry. Ann. Neurol. 1980, 8:590.
23. Dyck P.J., Turner D.W., Davies J.L., et al. Electronic case-report forms of symptoms and impairments of peripheral neuropathy. Can. J. Neurol. Sci. 2002, 29:258. for the rhNGF Group.
24. Dyck P.J., Velosa J.A., Pach J.M., et al. Increased weakness after pancreas and kidney transplantation. Transplantation 2001, 72:1403.
25. Dyck P.J.B., Norell J.E., Dyck P.J. Methylprednisolone may improve lumbosacral radiculoplexus neuropathy. Can. J. Neurol. Sci. 2001, 28:224.
26. Feldman E.L., Stevens M.J., Thomas P.K., et al. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care 1994, 17:1281.
27. The Guarantors of Brain Aids to the Examination of the Peripheral Nervous System 2001, 62. W. B. Saunders, Philadelphia.
28. Herndon R.M. Handbook of Neurologic Rating Scales 1997, 266. Demos Vermande, New York.
29. Hughes R., Bensa S., Willison H., et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann. Neurol. 2001, 50:195. for the European Inflammatory Neuropathy Cause and Treatment (INCAT) Group.
30. Hughes R.A., Raphael J.C., Swan A.V., vanDoorn P.A Intravenous immunoglobulin for Guillain-Barre syndrome (Cochrane Review). The Cochrane Library, Issue 4 2003, John Wiley and Sons Ltd., Chichester, U K.
31. Hughes R.A.C., Newsom-Davis J.M., Perkin G.D., Pierce J.M. Controlled trial of prednisolone in acute polyneuropathy. Lancet 1978, 2:750.
32. Hughes R.A.C., van der Meche F.G.A. Corticosteroid treatment for Guillain-Barre syndrome (Cochrane Review). The Cochrane Library, Issue 4 1999, John Wiley and Sons Ltd., Chichester, U K.
33. Klein C.J., Cunningham J.M., Atkinson E.J., et al. The gene for HMSN 2C maps to 12q23-24: a region of neuromuscular disorders. Neurology 2003, 60:1151.
34. Kleyweg R.P., van der Meche F.G., Schmitz P.I. Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barre syndrome. Muscle Nerve 1991, 14:1103.
35. Krupp L.B., LaRocca N.G., Muir-Nash J., Steinberg A.D. The fatigue severity scale: application to patients with multiple sclerosis and systemic lupus erythematosus. Arch. Neurol. 1989, 46:1121.
36. Lovett R.W. The Treatment of Infantile Paralysis 1917, P. Blakiston's Son & Co., Philadelphia.
37. Martina I.S., vanKoningsveld R., Schmitz P.I., for the European Inflammatory Neuropathy Cause and Treatment (INCAT) Group, et al. Measuring vibration threshold with a graduated tuning fork in normal aging and in patients with polyneuropathy. J. Neurol. Neurosurg. Psychiatry 1998, 65:743.
38. Medical Research Council Aids to the Investigation of Peripheral Nerve Injuries (War Memorandum No. 7) 1943, The White Rose Press, London, Her Majesty's Stationery Office.
39. Members of the Sections of Neurology and Section of Physiology, Mayo Clinic and Mayo Foundation Clinical Examinations in Neurology 1956, 370. W. B. Saunders, Philadelphia.
40. Mendell J.R., Barohn R.J., Freimer M.L., et al. Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2001, 56:445.
41. Merkies I.S., Schmitz P.I., Samijn J.P., for the European Inflammatory Neuropathy Cause and Treatment (INCAT) Group, et al. Fatigue in immune-mediated polyneu-ropathies. Neurology 1999, 53:1648.
42. Merkies I.S., Schmitz P.I., Samijn J.P., for the European Inflammatory Neuropathy Cause and Treatment (INCAT) Group, et al. Assessing grip strength in healthy individuals and patients with immune-mediated polyneuropathies. Muscle Nerve 2000, 23:1393.
43. Merkies I.S., Schmitz P.I., van der Meche F.G., vanDoorn P.A, for the European Inflammatory Neuropathy Cause and Treatment (INCAT) Group Psychometric evaluation of a new sensory scale in immune-mediated polyneu-ropathies. Neurology 2000, 54:943.
44. Merkies I.S., Schmitz P.I., van der Meche F.G., et al. Psychometric evaluation of a new handicap scale in immune-mediated polyneuropathies. Muscle Nerve 2002, 25:370.
45. Merkies I.S., Schmitz P.I., van der Meche F.G., et al. Clinimetric evaluation of a new overall disability scale in immune mediated polyneuropathies. J. Neurol. Neurosurg. Psychiatry 2002, 72:596. for the European Inflammatory Neuropathy Cause and Treatment (INCAT) Group.
46. Merkies I.S., Schmitz P.I., van der Meche F.G., for the European Inflammatory Neuropathy Cause and Treatment (INCAT) Group, et al. Quality of life complements traditional outcome measures in immune-mediated polyneuropathies. Neurology 2002, 59:84.
47. Mitchell S.W. Injuries of Nerves and Their Consequences 1872, 377. J. B. Lippincott, Philadelphia.
48. Munstat T.L. Quantification of Neurologic Deficit 1989, 357. Butterworth, Boston.
49. Office of Disability Disability Evaluation under Social Security 1986, 102. Social Security Administration, Baltimore.
50. Porter R.J., Schoenberg B.S. Controlled Clinical Trials in Neurological Disease 1990, 440. Kluwer Academic Publishers, Boston.
51. Potvin A.R., Tourtellotte W.W., Potvin J.H., et al. Quantitative Examination of Neurologic Functions 1985, 205. CRC Press, Boca Raton, FL.
52. Rankin J. Cerebral vascular accidents in patients over the age of 60. 2. Prognosis. Scott. Med. J. 1957, 2:200.
53. Raphael J.-C., Chevret S., Hughes R.A.C., Annane D. Plasma exchange for Guillain-Barre syndrome (Cochrane Review). The Cochrane Library, Issue 4 2001, John Wiley and Sons Ltd., Chichester, U K.
54. Rydel A., Seiffer W. Untersuchungen uber das vibrationsqefuhl oder die sog: "Knochensensibilitat" (Pallasthesie). Arch. Psychiatr. Nervenkrankenh. 1903, 37:488.
55. Sharrack B., Hughes R.A. The Guy's Neurological Disability Scale (GNDS): a new disability measure for multiple sclerosis. Mult. Scler. 1999, 5:223.
56. Sharrack B., Hughes R.A., Soudain S., Dunn G. The psychometric properties of clinical rating scales used in multiple sclerosis. Brain 1999, 122:141.
57. Skljarevski V., Price K.L., Bastyr E.J., et al. Limited neurological examination of the legs correlates with composite measures of nerve conduction in patients with diabetic peripheral neuropathy. Eur. J. Neurol. 2003, 10(Suppl. 1):122.
58. World Health Organization Classification of Impairments: International Classification of Impairments, Disabilities and Handicaps 1980, 47. World Health Organization, Geneva.
59. World Health Organization ICIDH-2: International Classification of Impairments, Activities, and Participation 1997, 1. World Health Organization, Geneva.
60. Ziegler D., Hanefeld M., Ruhnau K.J., et al. Treatment of symptomatic diabetic peripheral neuropathy with the antioxidant alpha-lipoic acid: a 3-week multicenter randomized controlled trial (ALADIN Study). Diabetologia 1995, 38:1425.